These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 832522)

  • 41. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.
    Sastry S; Clarke LG; Alrowais H; Querry AM; Shutt KA; Doi Y
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7355-61. PubMed ID: 26369978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Fosfomycin. II. Antimicrobial activity in vivo].
    Carlone NA; Cuffini AM; Savoia D
    G Batteriol Virol Immunol; 1977; 70(7-12):215-25. PubMed ID: 615746
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection.
    Stein GE
    Clin Ther; 1999 Nov; 21(11):1864-72. PubMed ID: 10890258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical studies on fosfomycin sodium following intravenous administration (tissue concentration and clinical efficacy)].
    Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E
    Jpn J Antibiot; 1985 Aug; 38(8):2057-67. PubMed ID: 4079000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
    Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
    Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical bacteriological evaluation of infantile bacteriuria treated with fosfomycin.
    Ureta A; Magariños JI; Sousa AS
    Chemotherapy; 1977; 23 Suppl 1():324-30. PubMed ID: 832532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Evaluation on ceftriaxone in the pediatric field].
    Nakazawa S; Satoh H; Niino K; Hirama Y; Narita A; Suzuki H; Nakazawa S; Chikaoka H; Tazoe K
    Jpn J Antibiot; 1984 Nov; 37(11):2083-101. PubMed ID: 6098703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical evaluation of fosfomycin dry syrup (author's transl)].
    Osamu S; Naomichi W; Hironari F; Yuichi K; Susumu H
    Jpn J Antibiot; 1976 Apr; 29(4):351-7. PubMed ID: 778427
    [No Abstract]   [Full Text] [Related]  

  • 50. Fosfomycin: Absorption and excretion.
    Shimizu K
    Chemotherapy; 1977; 23 Suppl 1():153-8. PubMed ID: 12926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study.
    Rudenko N; Dorofeyev A
    Arzneimittelforschung; 2005; 55(7):420-7. PubMed ID: 16080282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evaluation of effectiveness of rokitamycin dry syrup in acute enteritis in pediatrics. A comparative study on rokitamycin and fosfomycin dry syrups].
    Motohiro T; Aramaki M; Oda K; Kawakami A; Tanaka K; Koga T; Sakata Y; Yamashita F; Suzuki K; Ishii M
    Jpn J Antibiot; 1990 Feb; 43(2):257-84. PubMed ID: 2194055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetic and clinical studies on cefpodoxime proxetil dry syrup in the field of pediatrics].
    Motohiro T; Oda K; Aramaki M; Kawakami A; Tanaka K; Koga T; Sakata Y; Fujimoto T; Yokochi K; Yamashita F
    Jpn J Antibiot; 1989 Jul; 42(7):1629-66. PubMed ID: 2681864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders].
    Tsuda S; Kuzuyama Y; Nakai H; Seriu T; Takashima T; Tanaka S; Horiike S; Taniwaki M; Misawa S; Kashima K
    Jpn J Antibiot; 1993 Feb; 46(2):171-83. PubMed ID: 8331778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fosfomycin: Laboratory studies.
    Woodruff HB; Mata JM; Hernández S; Mochales S; Rodríguez A; Stapley EO; Wallick H; Miller AK; Hendlin D
    Chemotherapy; 1977; 23 Suppl 1():1-22. PubMed ID: 583866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Therapeutic effects of cefmenoxime in the treatment of various infections on infants and children].
    Kurashige T; Wakiguchi H; Kitamura I; Ozaki H; Nishibayashi Y; Hamawaki M
    Jpn J Antibiot; 1982 Nov; 35(11):2579-88. PubMed ID: 6302339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Experimental and clinical evaluation of a new cephamycin antibiotic, cefotetan, in pediatrics].
    Nakazawa S; Sato H; Niino K; Suzuki H; Nakazawa S; Chikaoka H; Oka S; Hirama Y; Narita A
    Jpn J Antibiot; 1983 Jun; 36(6):1219-32. PubMed ID: 6581328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.
    Trinh TD; Smith JR; Rybak MJ
    Pharmacotherapy; 2019 Nov; 39(11):1077-1094. PubMed ID: 31487056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical results of cefpiramide therapy in infections of children].
    Nagamatsu I; Okuno A
    Jpn J Antibiot; 1983 Aug; 36(8):2147-52. PubMed ID: 6655834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.